| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.0105-2896.2005.00219.X |
| P698 | PubMed publication ID | 15790349 |
| P2093 | author name string | Susan L Kalled | |
| P2860 | cites work | BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth | Q22009942 |
| TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 | ||
| Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS | Q24290135 | ||
| Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein | Q24291950 | ||
| Impaired IgA class switching in APRIL-deficient mice | Q24313032 | ||
| NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily | Q24314630 | ||
| BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2 | Q27639845 | ||
| Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI | Q28140973 | ||
| Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency | Q28190857 | ||
| Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival | Q28205125 | ||
| BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases | Q28205999 | ||
| BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF | Q28213294 | ||
| APRIL-deficient mice have normal immune system development | Q28511017 | ||
| BCMA is essential for the survival of long-lived bone marrow plasma cells | Q28587037 | ||
| Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice | Q28587370 | ||
| B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells | Q28590517 | ||
| B cell depletion in autoimmune disease | Q33361142 | ||
| Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus | Q33928629 | ||
| Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. | Q33951524 | ||
| Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor | Q34178508 | ||
| BAFF AND APRIL: a tutorial on B cell survival | Q34994661 | ||
| Pathogenic roles of B cells in human autoimmunity; insights from the clinic | Q35772863 | ||
| The complement system in B cell regulation | Q35781836 | ||
| Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. | Q36369679 | ||
| Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells | Q36371743 | ||
| Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations | Q36375661 | ||
| Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires | Q37689611 | ||
| Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain | Q40941667 | ||
| G-CSF-stimulated neutrophils are a prominent source of functional BLyS | Q41818295 | ||
| Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells | Q42079747 | ||
| Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus | Q42211312 | ||
| Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients | Q42619341 | ||
| BAFF mediates survival of peripheral immature B lymphocytes | Q42944182 | ||
| The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome | Q43050637 | ||
| T cell costimulation by the TNF ligand BAFF. | Q43803679 | ||
| Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. | Q44021488 | ||
| Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. | Q44223059 | ||
| Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function | Q44504176 | ||
| CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+T cells | Q45971909 | ||
| B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. | Q46001110 | ||
| Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. | Q46109491 | ||
| Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis | Q46397162 | ||
| Requirements for follicular exclusion and competitive elimination of autoantigen-binding B cells. | Q46482871 | ||
| Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. | Q46863693 | ||
| Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate | Q46900158 | ||
| Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis | Q47274470 | ||
| Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function | Q47283207 | ||
| Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. | Q47365613 | ||
| Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome | Q47739038 | ||
| BAFF production by antigen-presenting cells provides T cell co-stimulation. | Q51025017 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Dependence of germinal center B cells on expression of CD21/CD35 for survival. | Q52039603 | ||
| B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. | Q54707196 | ||
| Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome | Q57212191 | ||
| An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway | Q57230082 | ||
| Plasma levels of B-lymphocyte stimulator increase with HIV disease progression | Q57387720 | ||
| P921 | main subject | immune function | Q124683452 |
| P304 | page(s) | 43-54 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Immunological Reviews | Q15724582 |
| P1476 | title | The role of BAFF in immune function and implications for autoimmunity | |
| P478 | volume | 204 |
| Q34416115 | A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study |
| Q84104588 | Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients |
| Q36394955 | An APRIL to remember: novel TNF ligands as therapeutic targets |
| Q28303311 | An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity |
| Q35334977 | Antigen is required for maturation and activation of pathogenic anti-DNA antibodies and systemic inflammation |
| Q24628925 | Atacicept: targeting B cells in multiple sclerosis |
| Q34544062 | B cells move to centre stage: novel opportunities for autoimmune disease treatment |
| Q37009908 | B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation |
| Q37690672 | B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis |
| Q40059905 | B-cell activating factor BAFF reflects patients' immunological risk profile after kidney transplantation. |
| Q36778126 | B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma |
| Q42038591 | B-cell tolerance in transplantation: is repertoire remodeling the answer? |
| Q34159016 | B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. |
| Q58225712 | BAFF costimulation of Toll-like receptor-activatedB-1 cells |
| Q36443689 | Contemporary treatment of systemic lupus erythematosus: an update for clinicians. |
| Q36491362 | Control of canonical NF-kappaB activation through the NIK-IKK complex pathway |
| Q33440567 | Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells |
| Q42510282 | Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells |
| Q33716235 | Differences in mouse and human nonmemory B cell pools |
| Q39485889 | Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis |
| Q36662159 | IL5RA and TNFRSF6B gene variants are associated with sporadic IgA nephropathy |
| Q92101160 | Immunological Characteristics in Refractory Chronic Rhinosinusitis with Nasal Polyps Undergoing Revision Surgeries |
| Q90479619 | Impact of BAFF Blockade on Inflammation, Germinal Center Reaction and Effector B-Cells During Acute SIV Infection |
| Q34503355 | Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human |
| Q37810517 | Janus head: the dual role of HLA-G in CNS immunity |
| Q37177128 | Manipulating B cell homeostasis: a key component in the advancement of targeted strategies |
| Q34434727 | MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts |
| Q37968620 | Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. |
| Q28068695 | Multiple Roles for B-Lymphocytes in Sjogren's Syndrome |
| Q36384731 | Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival |
| Q34044394 | Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice |
| Q39985668 | Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice |
| Q64044243 | Recent advances in the management of systemic lupus erythematosus |
| Q41970239 | Selective regulation of autoreactive B cells by FcgammaRIIB. |
| Q36622367 | The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity |
| Q33748041 | The function of BAFF on T helper cells in autoimmunity |
| Q24682937 | The riddle of the dual expression of IgM and IgD |
| Q33385389 | Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders |
| Q51890165 | [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis]. |
| Q84600763 | [New therapeutic targets] |
| Q51958899 | [Targeting B cells in multiple sclerosis. Current concepts and strategies]. |
Search more.